CERUS CORP (CERS) Fundamental Analysis & Valuation

NASDAQ:CERS • US1570851014

Current stock price

2.05 USD
-0.03 (-1.44%)
At close:
1.9708 USD
-0.08 (-3.86%)
After Hours:

This CERS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. CERS Profitability Analysis

1.1 Basic Checks

  • CERS had negative earnings in the past year.
  • CERS had a positive operating cash flow in the past year.
  • In the past 5 years CERS always reported negative net income.
  • In multiple years CERS reported negative operating cash flow during the last 5 years.
CERS Yearly Net Income VS EBIT VS OCF VS FCFCERS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M

1.2 Ratios

  • With a decent Return On Assets value of -7.04%, CERS is doing good in the industry, outperforming 66.84% of the companies in the same industry.
  • With a Return On Equity value of -24.33%, CERS perfoms like the industry average, outperforming 57.22% of the companies in the same industry.
Industry RankSector Rank
ROA -7.04%
ROE -24.33%
ROIC N/A
ROA(3y)-12.14%
ROA(5y)-15.79%
ROE(3y)-44.26%
ROE(5y)-52.08%
ROIC(3y)N/A
ROIC(5y)N/A
CERS Yearly ROA, ROE, ROICCERS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • The Gross Margin of CERS (59.86%) is better than 60.96% of its industry peers.
  • CERS's Gross Margin has been stable in the last couple of years.
  • CERS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.2%
GM growth 5Y-1.33%
CERS Yearly Profit, Operating, Gross MarginsCERS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

3

2. CERS Health Analysis

2.1 Basic Checks

  • CERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CERS has been increased compared to 1 year ago.
  • Compared to 5 years ago, CERS has more shares outstanding
  • Compared to 1 year ago, CERS has an improved debt to assets ratio.
CERS Yearly Shares OutstandingCERS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
CERS Yearly Total Debt VS Total AssetsCERS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -3.98, we must say that CERS is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of CERS (-3.98) is worse than 69.52% of its industry peers.
  • The Debt to FCF ratio of CERS is 75.71, which is on the high side as it means it would take CERS, 75.71 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of CERS (75.71) is better than 65.78% of its industry peers.
  • CERS has a Debt/Equity ratio of 0.63. This is a neutral value indicating CERS is somewhat dependend on debt financing.
  • CERS has a Debt to Equity ratio of 0.63. This is in the lower half of the industry: CERS underperforms 66.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 75.71
Altman-Z -3.98
ROIC/WACCN/A
WACC8.74%
CERS Yearly LT Debt VS Equity VS FCFCERS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 1.73 indicates that CERS should not have too much problems paying its short term obligations.
  • CERS has a worse Current ratio (1.73) than 70.59% of its industry peers.
  • A Quick Ratio of 1.17 indicates that CERS should not have too much problems paying its short term obligations.
  • CERS has a Quick ratio of 1.17. This is in the lower half of the industry: CERS underperforms 73.80% of its industry peers.
Industry RankSector Rank
Current Ratio 1.73
Quick Ratio 1.17
CERS Yearly Current Assets VS Current LiabilitesCERS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

5

3. CERS Growth Analysis

3.1 Past

  • CERS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.27%, which is quite impressive.
  • CERS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.13%.
  • CERS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.41% yearly.
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)16.13%
Revenue growth 3Y7.48%
Revenue growth 5Y15.41%
Sales Q2Q%13.66%

3.2 Future

  • Based on estimates for the next years, CERS will show a very strong growth in Earnings Per Share. The EPS will grow by 48.50% on average per year.
  • CERS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.77% yearly.
EPS Next Y6.5%
EPS Next 2Y25.5%
EPS Next 3Y48.5%
EPS Next 5YN/A
Revenue Next Year9.45%
Revenue Next 2Y9.15%
Revenue Next 3Y8.77%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CERS Yearly Revenue VS EstimatesCERS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M 250M
CERS Yearly EPS VS EstimatesCERS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.2 -0.4 -0.6

2

4. CERS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CERS. In the last year negative earnings were reported.
  • Also next year CERS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CERS Price Earnings VS Forward Price EarningsCERS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, CERS is valued a bit cheaper than 65.24% of the companies in the same industry.
Industry RankSector Rank
P/FCF 355.55
EV/EBITDA N/A
CERS Per share dataCERS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • CERS's earnings are expected to grow with 48.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.5%
EPS Next 3Y48.5%

0

5. CERS Dividend Analysis

5.1 Amount

  • No dividends for CERS!.
Industry RankSector Rank
Dividend Yield 0%

CERS Fundamentals: All Metrics, Ratios and Statistics

CERUS CORP

NASDAQ:CERS (4/20/2026, 4:36:22 PM)

After market: 1.9708 -0.08 (-3.86%)

2.05

-0.03 (-1.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-02
Earnings (Next)04-30
Inst Owners76.44%
Inst Owner Change0%
Ins Owners3.91%
Ins Owner Change-0.36%
Market Cap393.95M
Revenue(TTM)233.80M
Net Income(TTM)-15.63M
Analysts80
Price Target5.1 (148.78%)
Short Float %6.06%
Short Ratio6.77
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)34.64%
Min EPS beat(2)-30.72%
Max EPS beat(2)100%
EPS beat(4)2
Avg EPS beat(4)17.24%
Min EPS beat(4)-30.72%
Max EPS beat(4)100%
EPS beat(8)5
Avg EPS beat(8)17.63%
EPS beat(12)7
Avg EPS beat(12)18.46%
EPS beat(16)10
Avg EPS beat(16)13.56%
Revenue beat(2)0
Avg Revenue beat(2)-3.77%
Min Revenue beat(2)-5.03%
Max Revenue beat(2)-2.51%
Revenue beat(4)0
Avg Revenue beat(4)-6.89%
Min Revenue beat(4)-14.57%
Max Revenue beat(4)-2.51%
Revenue beat(8)1
Avg Revenue beat(8)-5.4%
Revenue beat(12)1
Avg Revenue beat(12)-7.05%
Revenue beat(16)5
Avg Revenue beat(16)-3.28%
PT rev (1m)7.14%
PT rev (3m)7.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-33.33%
EPS NY rev (1m)-83.32%
EPS NY rev (3m)-83.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.68
P/FCF 355.55
P/OCF 81.44
P/B 6.13
P/tB 6.26
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)0.01
FCFY0.28%
OCF(TTM)0.03
OCFY1.23%
SpS1.22
BVpS0.33
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -7.04%
ROE -24.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.86%
FCFM 0.47%
ROA(3y)-12.14%
ROA(5y)-15.79%
ROE(3y)-44.26%
ROE(5y)-52.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.2%
GM growth 5Y-1.33%
F-Score5
Asset Turnover1.05
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 75.71
Debt/EBITDA N/A
Cap/Depr 261.5%
Cap/Sales 1.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.73
Quick Ratio 1.17
Altman-Z -3.98
F-Score5
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)197.11%
Cap/Depr(5y)137.46%
Cap/Sales(3y)1.82%
Cap/Sales(5y)1.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y6.5%
EPS Next 2Y25.5%
EPS Next 3Y48.5%
EPS Next 5YN/A
Revenue 1Y (TTM)16.13%
Revenue growth 3Y7.48%
Revenue growth 5Y15.41%
Sales Q2Q%13.66%
Revenue Next Year9.45%
Revenue Next 2Y9.15%
Revenue Next 3Y8.77%
Revenue Next 5YN/A
EBIT growth 1Y38.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year247.56%
EBIT Next 3Y92.87%
EBIT Next 5YN/A
FCF growth 1Y-87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.42%
OCF growth 3YN/A
OCF growth 5YN/A

CERUS CORP / CERS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for CERUS CORP?

ChartMill assigns a fundamental rating of 3 / 10 to CERS.


Can you provide the valuation status for CERUS CORP?

ChartMill assigns a valuation rating of 2 / 10 to CERUS CORP (CERS). This can be considered as Overvalued.


Can you provide the profitability details for CERUS CORP?

CERUS CORP (CERS) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for CERS stock?

The Earnings per Share (EPS) of CERUS CORP (CERS) is expected to grow by 6.5% in the next year.